Industry News

• U.S. Food And Drug Administration accepts New Drug Application  Bristol-Myers Squibb and AstraZeneca announced that the FDA has accepted for review a New Drug Application (NDA) for an investigational fixed dose combination of ONGLYZA(TM) (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor, and metformin HCl extended-release tablets.
  Bristol-Myers Squibb Company March 17, 2010  
• Study shows Prevenar 13* is immunogenic in young children previously vaccinated  According to results from a Phase III safety and immunogenicity study presented today, Prevenar 13* was shown to be immunogenic and generally well tolerated in healthy young children who had received at least three prior doses of Prevenar* (Pneumococcal Saccharide Conjugated Vaccine, Adsorbed).
  Pfizer Inc. March 17, 2010  
• Star Scientific regains compliance with NASDAQ  Star Scientific reported that after the close of trading on March 16 it received a letter from NASDAQ indicating that Star now has regained compliance with the NASDAQ minimum bid-price listing requirement.
  Star Scientific, Inc. March 16, 2010  
• Trimeris reports financial results for the fourth quarter and full year 2009  Trimeris reported net income of $7.2 million for the fourth quarter of 2009 compared with $1.5 million for the fourth quarter of 2008. Cash, cash equivalents and investment securities available-for-sale totaled $48.4 million at December 31, 2009, compared to $31.6 million at December 31, 2008.
  Trimeris, Inc. March 16, 2010  
• Boston Scientific completes enrollment in PLATINUM trials  Boston Scientific announced completion of patient enrollment in the Small Vessel and Long Lesion trials of its PLATINUM clinical program that are designed to compare the platinum chromium PROMUS® Element Everolimus-Eluting Stent System to matched historical control groups of patients.
  Boston Scientific Corporation March 16, 2010  
• New PLATO sub-analysis of CABG patients presented at ACC  AstraZeneca announced results of a new analysis of the PLATO study which showed there were fewer deaths in patients with acute coronary syndromes who took the investigational oral antiplatelet BRILINTA within seven days prior to having heart bypass surgery compared to those who took clopidogrel.
  AstraZeneca March 16, 2010  
• Additional $162 million in Recovery Act investment to advance health IT  U.S. Department of Health and Human Services Secretary Kathleen Sebelius announced awards to help states facilitate health information exchange and advance health information technology (health IT).
  Dept. of Health & Human Services March 15, 2010  
• Icagen reports positive results for ICA-105665 in patients with photosensitive epilepsy  Icagen reported positive results in its Phase IIa epilepsy study of ICA-105665, the Company's novel orally available small molecule KCNQ potassium channel agonist.
  Icagen, Inc. March 15, 2010  
• Lilly to acquire global license to AXIRON testosterone solution from Acrux  Eli Lilly and Company and Acrux announced that they have entered into an exclusive worldwide license agreement for the potential commercialization of Acrux's experimental underarm testosterone solution (proposed tradename AXIRON(TM)).
  Eli Lilly and Company March 15, 2010  
• Intensive Lipitor therapy was associated with reduced risk of cardiovascular events  Lipitor(R) (atorvastatin calcium) 80 mg was associated with a significantly reduced risk of major cardiovascular events compared with Lipitor 10 mg among patients with both coronary heart disease (CHD) and chronic kidney disease (CKD) who were obese or had metabolic syndrome.
  Pfizer Inc. March 15, 2010  

   (next 10 articles)